Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27889571 | 0.84 | OPRM1 (0.58) | KDM4EALDH1A1LMNAGFERNPSR1 | |
| SCHEMBL6701330 | 0.84 | ALDH1A1 (0.48) | KDM4EALDH1A1LMNAGFERNPSR1 | |
| SCHEMBL6700278 | 0.82 | KDM4E (0.64) | KDM4EALDH1A1LMNAGFERNPSR1 | |
| SCHEMBL10490290 | 0.82 | KDM4E (0.68) | KDM4EALDH1A1LMNAGFERNPSR1 | |
| SCHEMBL15800714 | 0.82 | KDM4E (0.71) | KDM4EALDH1A1LMNAGFERNPSR1 | |
| SCHEMBL6427613 | 0.80 | CHEK2 (0.64) | KDM4EALDH1A1MAPK1L3MBTL1KMT2A | |
| SCHEMBL2744427 | 0.80 | HTR2A (0.69) | MAPTL3MBTL1DRD4HTR2AHTR2C | |
| SCHEMBL28691451 | 0.79 | ALDH1A1 (0.64) | KDM4EALDH1A1LMNAGFERNPSR1 | |
| Hydrochloric Acid SCHEMBL9742137 | 0.79 | HTR2A (0.67) | MAPTL3MBTL1DRD4HTR2AHTR2C | |
| SCHEMBL10041818 | 0.78 | KDM4E (0.62) | KDM4EALDH1A1LMNAGFERNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | claimed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | claimed |
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | DAUGAN ALAIN CLAUDE-MARIE (FR) | 2004-03-04 | — | — | US | disclosed |
| WO-2003048121-A1 | THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | disclosed |
| EP-1286670-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001097810-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | MTTP, LIPC, CETP | KDM4E 2556/4885ALDH1A1 379/4885LMNA 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.